首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1547537

全球呼吸道病毒疫苗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Respiratory Virus Vaccines Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 222 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球呼吸道病毒疫苗市场需求预计将从2023年的109.5亿美元达到2032年近229.2亿美元的市场规模，2024-2032年研究期间的复合年增长率为8.55%。

疫苗是一种生物製剂，用于提供针对多种有害病原体的后天免疫力。它的目的是预防弱势群体罹患某种特定疾病。它含有一种病原体，即细菌或病毒株，能以弱化或灭活的形式引起特定疾病。呼吸系统疾病是一种影响肺部和身体呼吸系统其他部位的疾病。它可能是由于吸烟、被动吸烟、感染、石棉和其他类型的空气污染引起的。呼吸系统疾病包括气喘、肺纤维化、肺炎、慢性阻塞性肺病和肺癌。特定的疫苗可预防疾病会导致气道和肺部肿胀。两者混合会引发肺炎和各种真正的呼吸道疾病。免疫接种被认为是确保个人健康的最安全方法，无论患者是否服用处方药物。疫苗反应通常很轻微，并且会自行消失。严重的副作用极为罕见。

市场动态

该市场的推动因素包括呼吸道疾病盛行率的上升和试验中疫苗数量的增加，而交付基础设施不足和消费者意识有限是限制因素。透过各种市场合作增加研发支出和增加疫苗供应，为市场成长创造了机会。此外，呼吸道疫苗的研发目前主要集中在COVID-19；然而，长期前景仍然乐观。从 COVID-19 的影响中汲取经验，全球各国政府致力于开发适当的呼吸道疫苗治疗方案。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球呼吸道病毒疫苗市场的各个细分市场进行了包容性评估。呼吸道病毒疫苗产业的成长和趋势为本研究提供了整体方法。

市场区隔

呼吸道病毒疫苗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按类型

失活/杀死
疫苗
减毒活疫苗
重组疫苗

依给药途径

肌肉注射
鼻内
皮下

按指示

流感
麻疹、腮腺炎和德国麻疹
冠状病毒病（COVID-19）
其他的

按年龄段

儿科
成年人

按最终用户

医生办公室
医院
诊所
药房/商店

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲呼吸道病毒疫苗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。呼吸道病毒疫苗市场的主要参与者包括 CSL Limited、赛诺菲、阿斯特捷利康、默克公司、葛兰素史克公司、印度血清研究所。有限公司、巴拉特生物技术公司、科兴生物技术有限公司。开发、新产品发布，以及其他进度。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

简介 - 市场动态
市场驱动因素
市场限制
机会
产业动态
波特五力分析
市场吸引力分析
- 按类型分類的市场吸引力分析
- 按给药途径进行的市场吸引力分析
- 按指标进行的市场吸引力分析
- 按年龄组别分類的市场吸引力分析
- 最终用户的市场吸引力分析
- 市场吸引力分析：按地区

第 4 章：价值链分析

价值链分析
原料分析
- 原料清单
- 原料厂商清单
- 主要原物料价格走势
潜在买家名单
行销管道
- 直效行销
- 间接行销
- 行销通路发展趋势

第 5 章：全球呼吸道病毒疫苗市场分析：按类型

按类型概述
按类型分析历史和预测数据
失活/杀死
疫苗
减毒活疫苗
重组疫苗

第 6 章：全球呼吸道病毒疫苗市场分析：依给药途径

依给药途径概述
按给药途径进行历史和预测资料分析
肌肉注射
鼻内
皮下

第 7 章：全球呼吸道病毒疫苗市场分析：依适应症分类

按指示概述
按指示进行历史和预测资料分析
流感
麻疹、腮腺炎和德国麻疹
冠状病毒病（COVID-19）
其他的

第 8 章：全球呼吸道病毒疫苗市场分析：依年龄组别划分

按年龄组别概述
按年龄组别进行的历史和预测资料分析
儿科
成年人

第 9 章：全球呼吸道病毒疫苗市场分析：依最终用户分类

最终用户概述
最终用户的历史和预测数据分析
医生办公室
医院
诊所
药房/商店

第 10 章：全球呼吸道病毒疫苗市场分析：依地理位置

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 11 章：呼吸道病毒疫苗公司的竞争格局

呼吸道病毒疫苗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 12 章：公司简介

顶级公司市占率分析
市场集中度
CSL Limited

公司概况
公司收入
产品
最新动态

Sanofi

公司概况
公司收入
产品
最新动态

AstraZeneca

公司概况
公司收入
产品
最新动态

Merck & Co. Inc.

公司概况
公司收入
产品
最新动态

GlaxoSmithKline Plc

公司概况
公司收入
产品
最新动态

Serum Institute Of India Pvt. Ltd.

公司概况
公司收入
产品
最新动态

Bharat Biotech

公司概况
公司收入
产品
最新动态

Sinovac Biotech Ltd

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR11215029

The global demand for Respiratory Virus Vaccines Market is presumed to reach the market size of nearly USD 22.92 Billion by 2032 from USD 10.95 Billion in 2023 with a CAGR of 8.55% under the study period 2024-2032.

A vaccine is a biological preparation that is used to provide acquired immunity against numerous harmful pathogens. It is administered to prevent the vulnerable population from a specific disease. It contains an agent, i.e., bacteria or virus strain, which causes a particular disease in a weakened or killed form. Respiratory disease is a disease that impacts the lungs and other parts of the body's respiratory system. It can be caused due to smoking, passive smoking, infection, asbestos, and another type of air pollution. Respiratory diseases consist of asthma, pulmonary fibrosis, pneumonia, COPD, and lung cancer COPD and asthma cause breathing difficulty due to swelling of the air passage and blockage due to mucus. Specific vaccine-preventable diseases can cause swelling of air passage and lungs. The mixing of the two can prompt pneumonia and various genuine respiratory diseases. Immunization is considered the most secure way to ensure a person's wellbeing, regardless of whether the sufferer is taking prescribed medications. Vaccine reactions are generally mild and fade away on their own. Serious side effects are exceptionally uncommon.

MARKET DYNAMICS

The market is driven by factors such as the increasing prevalence of respiratory diseases and the increasing number of under-trial vaccines, whereas lack of inadequate delivery infrastructure and limited consumer awareness are restraining factors. Increasing expenditure on Research & Development and the growing availability of vaccines through various market collaborations create opportunities for market growth. In addition, R&D on respiratory vaccines is focused on COVID-19 at the moment; however, the long-term outlook remains positive. Learning from the impact of COVID-19, governments across the globe focus on developing adequate treatment options for respiratory vaccines.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Respiratory Virus Vaccines. The growth and trends of Respiratory Virus Vaccines industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Respiratory Virus Vaccines market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Inactivated/Killed
Vaccines
Live-attenuated Vaccines
Recombinant Vaccines

By Route of Administration

Intramuscular
Intranasal
Subcutaneous

By Indication

Influenza
Measles, Mumps & Rubella
Coronavirus Disease (COVID-19)
Others

By Age Group

Pediatric
Adults

By End User

Physician's Office
Hospitals
Clinics
Pharmacies/Stores

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Respiratory Virus Vaccines market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Respiratory Virus Vaccines market include CSL Limited, Sanofi, AstraZeneca, Merck & Co. Inc., GlaxoSmithKline Plc, Serum Institute Of India Pvt. Ltd., Bharat Biotech, Sinovac Biotech Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. RESPIRATORY VIRUS VACCINES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Indication
- 3.7.4 Market Attractiveness Analysis By Age Group
- 3.7.5 Market Attractiveness Analysis By End User
- 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Inactivated/Killed Historic and Forecast Sales By Regions
5.4. Vaccines Historic and Forecast Sales By Regions
5.5. Live-attenuated Vaccines Historic and Forecast Sales By Regions
5.6. Recombinant Vaccines Historic and Forecast Sales By Regions

6. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Intramuscular Historic and Forecast Sales By Regions
6.4. Intranasal Historic and Forecast Sales By Regions
6.5. Subcutaneous Historic and Forecast Sales By Regions

7. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY INDICATION

7.1. Overview By Indication
7.2. Historical and Forecast Data Analysis By Indication
7.3. Influenza Historic and Forecast Sales By Regions
7.4. Measles, Mumps & Rubella Historic and Forecast Sales By Regions
7.5. Coronavirus Disease (COVID-19) Historic and Forecast Sales By Regions
7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY AGE GROUP

8.1. Overview By Age Group
8.2. Historical and Forecast Data Analysis By Age Group
8.3. Pediatric Historic and Forecast Sales By Regions
8.4. Adults Historic and Forecast Sales By Regions

9. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY END USER

9.1. Overview By End User
9.2. Historical and Forecast Data Analysis By End User
9.3. Physician's Office Historic and Forecast Sales By Regions
9.4. Hospitals Historic and Forecast Sales By Regions
9.5. Clinics Historic and Forecast Sales By Regions
9.6. Pharmacies/Stores Historic and Forecast Sales By Regions

10. GLOBAL RESPIRATORY VIRUS VACCINES MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE RESPIRATORY VIRUS VACCINES COMPANIES

11.1. Respiratory Virus Vaccines Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12. COMPANY PROFILES OF RESPIRATORY VIRUS VACCINES INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. CSL Limited
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
12.4. Sanofi
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
12.5. AstraZeneca
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
12.6. Merck & Co. Inc.
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
12.7. GlaxoSmithKline Plc
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
12.8. Serum Institute Of India Pvt. Ltd.
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
12.9. Bharat Biotech
- 12.9.1 Company Overview
- 12.9.2 Company Revenue
- 12.9.3 Products
- 12.9.4 Recent Developments
12.10. Sinovac Biotech Ltd
- 12.10.1 Company Overview
- 12.10.2 Company Revenue
- 12.10.3 Products
- 12.10.4 Recent Developments